1. A108 USTEKINUMAB IV INDUCTION RESULTS IN CROHN'S DISEASE SYMPTOM IMPROVEMENT WITHIN THE FIRST WEEK IN ANTI-TNF REFRACTORY PATIENTS. (1st March 2018) Authors: Sandborn, W; Yeager, B; Gasink, C; Hoops, T; Gao, L; Wang, Y; Jacobstein, D; Lee, S D; Hanauer, S Journal: Journal of the Canadian Association of Gastroenterology Issue: Volume 1(2018)Supplement 2 Page Start: 165 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A80 ENDOSCOPIC HEALING WITH USTEKINUMAB IN CROHN'S DISEASE: THE UNITI ENDOSCOPY SUB-STUDY. (1st March 2018) Authors: Feagan, B G; Sandborn, W; Gasink, C; Chan, D; Lang, Y; Pollack, P; Hanauer, S; Wolf, D; Jacobstein, D; Johanns, J; Szapary, P; Rutgeerts, P Journal: Journal of the Canadian Association of Gastroenterology Issue: Volume 1(2018)Supplement 1 Page Start: 137 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Double blind, placebo controlled trial of metronidazole in Crohn's disease. Issue 9 (September 1991) Authors: Sutherland, L; Singleton, J; Sessions, J; Hanauer, S; Krawitt, E; Rankin, G; Summers, R; Mekhjian, H; Greenberger, N; Kelly, M Journal: Gut Issue: Volume 32:Issue 9(1991) Page Start: 1071 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Lifestyle, behaviour, and environmental modification for the management of patients with inflammatory bowel diseases: an International Organization for Study of Inflammatory Bowel Diseases consensus. (July 2022) Authors: Ananthakrishnan, Ashwin N; Kaplan, Gilaad G; Bernstein, Charles N; Burke, Kristin E; Lochhead, Paul J; Sasson, Alexa N; Agrawal, Manasi; Tiong, Jimmy Ho Tuan; Steinberg, Joshua; Kruis, Wolfgang; Steinwurz, Flavio; Ahuja, Vineet; Ng, Siew C; Rubin, David T; Colombel, Jean-Frederic; Gearry, Richard... Journal: Lancet gastroenterology and hepatology Issue: Volume 7:Number 7(2022) Page Start: 666 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. OC-005 A Multicenter, Double-Blind, Placebo (PBO)-Controlled Ph3 Study of Ustekinumab (UST), A Human IL-12/23P40 MAB, in Moderate-Severe Crohn's Disease (CD) Refractory to anti-TNFΑ: UNITI-1. (17th August 2016) Authors: Rutgeerts, P; Gasink, C; Blank, M; Lang, Y; Johanns, J; Gao, L-L; Sands, B; Hanauer, S; Feagan, B; Targan, S; Ghosh, S; de Villiers, W; Colombel, J-F; Lee, SD; Desreumaux, P; Loftus, EV; Vermeire, S; Sandborn, WJ Journal: Gut Issue: Volume 65(2016)Supplement 1 Page Start: A3 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. OC-007 A Multicenter, Double-Blind, Placebo (PBO)-Controlled Ph3 Study of Ustekinumab (UST), AHuman MAB to IL-12/23P40, IN PTS with Moderately-Severely Active Crohn's Disease (CD) Who are Naïve or not Refractory to anti-TNFΑ: UNITI-2. (17th August 2016) Authors: Feagan, B; Gasink, C; Lang, Y; Friedman, JR; Johanns, J; Gao, L-L; Sands, B; Hanauer, S; Rutgeerts, P; Targan, S; Ghosh, S; de Villiers, W; Colombel, J-F; Tulassay, Z; Seidler, U; Sandborn, WJ Journal: Gut Issue: Volume 65(2016)Supplement 1 Page Start: A6 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. OC-043 Long term efficacy and safety of ustekinumab for crohn's disease: results from im-uniti long-term extension through 2 years. (17th June 2017) Authors: Sandborn, WJ; Rutgeerts, P; Gasink, C; Jacobstein, D; Gao, L; Johanns, J; Sands, B; Hanauer, S; Targan, S; Ghosh, S; Villiers, WJS de; Colombel, JF; Feagan, BG Journal: Gut Issue: Volume 66(2017)Supplement 2 Page Start: A22 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. OC-057 A PH3 Randomised, Multicenter, Double-Blind, Placebo (PBO)-Controlled Study of Ustekinumab (UST) Maintenance Therapy in Moderate–Severe Crohn's Disease (CD) PTS: Results from IM-UNITI. (17th August 2016) Authors: Sandborn, WJ; Feagan, BG; Gasink, C; Jacobstein, D; Gao, L-L; Johanns, J; Sands, B; Hanauer, S; Targan, S; Ghosh, S; de Villiers, W; Colombel, J-F; Lee, SD; Dieleman, L; Katz, S; Rutgeerts, P Journal: Gut Issue: Volume 65(2016)Supplement 1 Page Start: A32 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. P186 Outcomes of maintenance ustekinumab therapy for Crohn's disease based on inflammatory burden: A post-hoc analysis of the UNITI trials. (16th January 2018) Authors: Ghosh, S; Sattin, B; Tornatore, V; Gasink, C; Gao, L -L; Sloan, S; Rutgeerts, P; Sands, B; Hanauer, S; Feagan, B Journal: Journal of Crohn's and colitis Issue: Volume 12:Number 1(2018:Jan.)Supplement 1 Page Start: S192 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. P418 Safety and efficacy of olorinab, a peripherally restricted, highly-selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. (25th January 2019) Authors: Higgins, P; Ginsburg, D; Gilder, K; Gilder, K; Walsh, B; English, B; Turner, S; Klassen, P; Hanauer, S; Barish, C; Yacyshyn, B Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S318 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗